Adam Crystal, who serves as President of Research and Development at Tango Therapeutics, Inc. (NASDAQ:TNGX), disclosed a sale of 38,460 shares of the company’s common stock at $25.00 per share, for gross proceeds of $961,500, according to a Form 4 filing submitted to the Securities and Exchange Commission.
The filing records that the transaction took place on April 15, 2026. On that same date, Crystal exercised stock options to acquire 38,460 shares at an exercise price of $5.20 per share, representing a total cash outlay of $199,992 to effect the option exercise.
Following the reported sale, Crystal is listed as the direct owner of 112,622 shares of Tango Therapeutics common stock.
Tango’s shares have been trading close to a 52-week high of $26. The stock has posted an extraordinary climb of more than 1,840% over the past year. Market commentary noted in the filing references InvestingPro analysis that characterizes the shares as appearing overvalued at current levels. The InvestingPro note also indicates the availability of 18 additional tips and extensive research resources, including Pro Research Reports covering over 1,400 U.S. equities.
Separate corporate developments at Tango include the appointment of Matthew Gall as chief financial officer. The company said Gall joins Tango with prior experience at Kalaris Therapeutics and iTeos Therapeutics.
On the financial front, Tango reported a net loss of $38.7 million for the fourth quarter of 2025 and a net loss of $101.6 million for the full year. The company did not hold an earnings call in connection with those results.
Analyst houses have been revising their projections and price targets for Tango in light of recent program results and strategic arrangements. Leerink Partners raised its price target to $28 from $19, citing an increased probability of success for the company’s PRMT5 inhibitor program in pancreatic ductal adenocarcinoma. Stifel boosted its target to $24 from $15 and maintained a Buy rating, pointing to developments with the PRMT5 inhibitor and RAS(ON) combination approaches. Jefferies lifted its target to $18 from $14 and highlighted a supply agreement with ERAS for pan-RAS as a factor in its update. Those adjustments were described as reflecting analyst optimism following positive trial results and strategic agreements.
The insider transaction, the executive-level hire, the reported losses for the quarter and full year, and the analyst target changes together form the immediate public record of activity affecting Tango Therapeutics. The filing establishes the timing and mechanics of Crystal’s exercise-and-sale transaction but does not include commentary from the company or the insider beyond the disclosure required by the SEC filing.